PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 10, 2026Expert Opinion on Biological Therapy0 citations

Itepekimab for chronic obstructive pulmonary disease therapy

View Full Paper
SASabina A AntoniuTPTheodor PenisoaraȘRȘtefan Rașcu

Key Points

  • The study aims to evaluate itepekimab as a feasible therapy for managing chronic obstructive pulmonary disease (COPD).
  • Review existing clinical data on itepekimab.
  • Assess dosing schedules for different disease phases.
  • Focus on home administration of therapy.
  • Itepekimab may provide effective management for COPD.
  • Dosing can be adjusted to every 2 weeks during exacerbations and every 4 weeks when stable.

Abstract

Based on existing clinical data, itepekimab may be a potential therapy for COPD that can be easily administered at home, with dosing tailored to the disease phase (every 2 weeks during exacerbation and every 4 weeks during stable state).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Antoniu et al. (2026) studied this question.

synapsesocial.com/papers/69d895be6c1944d70ce06da3https://doi.org/10.1080/14712598.2026.2654773
Ask AI
Helpful
Bookmark
Share
View Full Paper